
Provider of Comprehensive Endoscopic Interventional Diagnosis and Treatment Solutions
Ophthalmic New Drug and Therapeutic Device R&D Provider

Supplier of Single-Cell Precision Diagnosis Technology R&D and Clinical Applications

Honor Express
Honor
DaoTong InvestmentRankedNational High-Performance Medical Device Innovation CenterTop Investment Institutions in the Medical Device Industry 2025". DaoTong Family EnterprisesMacroLux, Raytne, Polaris BiologyMultiple companies, including Polaris Biology, MacroLux, and Raytne, have been honored on the "2025 Top 100 Emerging Medical Device Companies" list.
To fully leverage the leading and radiating role of national-level innovation platforms, further activate industrial innovation momentum, effectively promote the high-quality development of the high-performance medical device industry, and accelerate the cultivation of new productive forces in China's medical equipment sector, the National Innovation Center for High-Performance Medical Devices has initiated and organized the "2025 Annual Medical Device Industry Innovation Ecosystem Insight Assessment."
DaoTong Investment
Top Investment Institutions in the Medical Device Industry 2025

Daotong Family Enterprises
Polaris Biology,MacroLux, Raytne
Top 100 Emerging Companies in the Medical Device Industry 2025 Innovation Index

DaoTong Family EnterpriseRaytne
2025 Medical Device Industry Ophthalmology Diagnosis and Treatment Field Innovation Index

United in purpose, steady in action, and visionary in progress, Dao Tong has developed intoLeading in ChinaIndustrial investment institutions, with in-depth presence in the fields of medical devices, innovative technologies, and biomedicine.Systematic Layoutand investment, achieving excellent investment performance and many successful cases. As an early to mid-stage investment institution, we are pleased to see the value brought by perseverance. The results of several innovative technology investments from our earlier layout are now bearing fruit, with multiple projects achieving technological innovation outcomes.The First in China。
In the future, Dao Tong Investment will continue to focus on its professional investment areas, persistently strive forward, support more outstanding companies in achieving leapfrog growth, and create value for the advancement and development of the medical industry.
END



ID:daltonventure
Long press to follow
RECOMMEND
Recommended Reading
Dalton Honor
DaoTong Investment Honored in CVSource’s 2022 “Top 100 Best Venture Capital Institutions in China”
Sun Qi of Daotong Investment Selected for "CVSource 2020 Top 50 Best Early-Stage Investors in China"
Daotong Investment Ranked Among "Top 40 Most LP-Favored Investment Institutions of 2020-2021"
Daotong Investment Honored as CVCRI "Top 30 Best Healthcare Investment Institutions in China 2020"